Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor

Department of Endocrinology, Klinikum Benjamin Franklin, Freie Universitat Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. LepeniesQuinkler@compuserve.com

OBJECTIVE: Progesterone binds to the human mineralocorticoid receptor (hMR) with nearly the same affinity as do aldosterone and cortisol, but confers only low agonistic activity. It is still unclear how aldosterone can act as a mineralocorticoid in situations with high progesterone concentrations, e.g. pregnancy. One mechanism could be conversion of progesterone to inactive compounds in hMR target tissues. DESIGN: We analyzed the agonist and antagonist activities of 16 progesterone metabolites by their binding characteristics for hMR as well as functional studies assessing transactivation. METHODS: We studied binding affinity using hMR expressed in a T7-coupled rabbit reticulocyte lysate system. We used co-transfection of an hMR expression vector together with a luciferase reporter gene in CV-1 cells to investigate agonistic and antagonistic properties. RESULTS: Progesterone and 11beta-OH-progesterone (11beta-OH-P) showed a slightly higher binding affinity than cortisol, deoxycorticosterone and aldosterone. 20alpha-dihydro(DH)-P, 5alpha-DH-P and 17alpha-OH-P had a 3- to 10-fold lower binding potency. All other progesterone metabolites showed a weak affinity for hMR. 20alpha-DH-P exhibited the strongest agonistic potency among the metabolites tested, reaching 11.5% of aldosterone transactivation. The agonistic activity of 11beta-OH-P, 11alpha-OH-P and 17alpha-OH-P was 9, 5.1 and 4.1% respectively. At a concentration of 100 nmol/l, progesterone, 17alpha-OH-P and 20alpha-DH-P inhibit nearly 75, 40 and 35% of the transactivation by aldosterone respectively. All other progesterone metabolites tested demonstrate weaker affinity, and agonistic and antagonistic potency. CONCLUSIONS: The binding affinity for hMR and the agonistic and antagonistic activity diminish with increasing reduction of the progesterone molecule at C20, C17 and at ring A. We assume that progesterone metabolism to these compounds is a possible protective mechanism for hMR. 17alpha-OH-P is a strong hMR antagonist and could exacerbate mineralocorticoid deficiency in patients with congenital adrenal hyperplasia.

This article has been cited by other articles:

				G. A. Molnar, C. Lindschau, G. Dubrovska, P. R. Mertens, T. Kirsch, M. Quinkler, M. Gollasch, S. Wresche, F. C. Luft, D. N. Muller, et al. Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells Hypertension, May 1, 2008; 51(5): 1372 - 1378. [Abstract] [Full Text] [PDF]

				A. Balsamo, A. Cicognani, M. Gennari, W. G Sippell, S. Menabo, F. Baronio, and F. G Riepe Functional characterization of naturally occurring NR3C2 gene mutations in Italian patients suffering from pseudohypoaldosteronism type 1 Eur. J. Endocrinol., February 1, 2007; 156(2): 249 - 256. [Abstract] [Full Text] [PDF]

				F. G. Riepe, J. Finkeldei, L. de Sanctis, S. Einaudi, A. Testa, B. Karges, M. Peter, M. Viemann, J. Grotzinger, W. G. Sippell, et al. Elucidating the Underlying Molecular Pathogenesis of NR3C2 Mutants Causing Autosomal Dominant Pseudohypoaldosteronism Type 1 J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4552 - 4561. [Abstract] [Full Text] [PDF]

				E. D. Szmuilowicz, G. K. Adler, J. S. Williams, D. E. Green, T. M. Yao, P. N. Hopkins, and E. W. Seely Relationship between Aldosterone and Progesterone in the Human Menstrual Cycle J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3981 - 3987. [Abstract] [Full Text] [PDF]

				J. Seidlerova, J. A. Staessen, M. Maillard, T. Nawrot, H. Zhang, M. Bochud, T. Kuznetsova, T. Richart, L. M. Van Bortel, H. A. Struijker-Boudier, et al. Association Between Arterial Properties and Renal Sodium Handling in a General Population Hypertension, October 1, 2006; 48(4): 609 - 615. [Abstract] [Full Text] [PDF]

				M. L. Hultman, N. V. Krasnoperova, S. Li, S. Du, C. Xia, J. D. Dietz, D. S. Lala, D. J. Welsch, and X. Hu The Ligand-Dependent Interaction of Mineralocorticoid Receptor with Coactivator and Corepressor Peptides Suggests Multiple Activation Mechanisms Mol. Endocrinol., June 1, 2005; 19(6): 1460 - 1473. [Abstract] [Full Text] [PDF]

				J. C. L. Leo, C. Guo, C. T. Woon, S. E. Aw, and V. C. L. Lin Glucocorticoid and Mineralocorticoid Cross-Talk with Progesterone Receptor to Induce Focal Adhesion and Growth Inhibition in Breast Cancer Cells Endocrinology, March 1, 2004; 145(3): 1314 - 1321. [Abstract] [Full Text] [PDF]

				M. Quinkler, B. Meyer, W. Oelkers, and S. Diederich Renal Inactivation, Mineralocorticoid Generation, and 11{beta}-Hydroxysteroid Dehydrogenase Inhibition Ameliorate the Antimineralocorticoid Effect of Progesterone in Vivo J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3767 - 3772. [Abstract] [Full Text] [PDF]

				M. Quinkler, C. Bumke-Vogt, B. Meyer, V. Bahr, W. Oelkers, and S. Diederich The Human Kidney Is a Progesterone-Metabolizing and Androgen-Producing Organ J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2803 - 2809. [Abstract] [Full Text] [PDF]